C Diff Drug Development

The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.

Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market Size, Share & Trends Analysis Report by Type (FMT, Microbiome Drugs),...

The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.

Recursion has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic.

/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the...

By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...

Interesting new findings on the differences in nutrient use by our gut bacteria. Are we ready for personalized dietary advice based on microbiome preferences rather than food pyramids?https://t.co/qUH72R0ymM— GutMicrobiota Health (@GMFHx) September 8, 2022

A new study suggests that the natural compound hydroquinine may be effective in fighting multidrug-resistant bacteria, including some that cause hospital infections.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

Join Acurx Pharmaceuticals' Executive Chairman, Robert Deluccia today at 12:00 PM as he discusses the Company's development of Ibezapolstat for the potential treatment of #CDiff. https://t.co/I6ffQbrRiC— Antimicrobials Working Group (@AWG_News) September 7, 2022

.@gianluca1aniro: Alternatives of FMT include defined microbial consortia such as RBX2660 and SER-109 that have shown durable engraftment and good safety profile @esnm_eu #GMFHCoverage pic.twitter.com/I2zOzscgLB— GutMicrobiota Health (@GMFHx) September 6, 2022

By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...

Seres Therapeutics Announces Completion of Rolling Bla Submission to FDA for Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection.Seres Therapeutics Inc - Anticipated Product Launch in First Half of 2023.

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

* Immuron approved to commence clinical study in c.difficile infection (cdi)

The FDA's #VRBPAC will meet on September 22 to review data supporting the biologics license application (BLA) for @Rebiotix's RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent #CDiff after antibiotic treatment. https://t.co/GClrIVBPna— MTIG (@MTIG_News) August 22, 2022

Four novel vaccine candidates developed by a University of Guelph chemist have been recently recognized by the World Health Organization (WHO) for potential use in treating what medical experts call a…

In a recent report, the World Health Organization recognized four vaccine candidates developed by U of G prof Mario Monteiro and his research team

An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB...

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019, unde

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Background: Clostridium difficile infection (CDI) has been widely reported in human and animals around the world over the past few decades. The high relapse rate and increasing drug resistance of CDI make the discovery of new agents against C. difficile fairly urgent. This study …

Kefir, a fermented beverage made from kefir grains, has gained immense popularity around the world due to its potential health-promoting properties. Kefir beverages are both marketed commerciall...

Scientists have created a probiotic to restore bile salt metabolism found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).

Clostridioides difficile infection is a global health threat and remains the primary cause of hospital-acquired infections worldwide. The burgeoning incidence and severity of infections coupled with high rates of recurrence have created an urgent need for novel therapeutics. Here, we report a novel …